Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: clinical trials returned 119 record(s)
|
|
Sunday, 07/29/2018
|
Using Historical Controls in CNS Clinical Trials
Xiang Ling, FDA/CDER/OTS/OB; Kun Jin, FDA; Hsien-Ming James Hung, PhD, Food and Drug Administration
2:05 PM
|
Statistical Development in Addressing Delayed Treatment Effect or Crossing Survival Curves in Immuno-Oncology Clinical Trials
Huyuan Yang, Takeda Oncology Pharmaceutical
2:20 PM
|
Designing Trials Using Bayesian Methods with Historical Controls
Michael Sonksen, Eli Lilly and Company
2:25 PM
|
An Adaptive Test of Significance in the Presence of Uncertainty in the Timing of the Final Analysis
Jeremy Gorelick, Edwards Lifesciences
2:35 PM
|
Advancing Methodologies for Clinical Trials Using Historical Control
Min Min, U.S. Food and Drug Administration, CDER/OTS/OB; Yeh-Fong Chen, US FDA
2:45 PM
|
Dose Selection Using Nonlinear Mixed-Effect Model Averaging Approaches in Conjunction with Adaptive Optimal Design Techniques
Andrew Hooker, Uppsala Universitet
2:45 PM
|
Leveraging Existing Information in Medical Device Clinical Trials
Rajesh Nair, CDRH/FDA; Xuefeng Li, CDRH/FDA; Laura Thompson, CDRH/FDA
3:05 PM
|
Correlation Between the Time-To-Event Endpoints in Prostate Cancer Clinical Trials
Susan Li, Janssen R&D
3:05 PM
|
Sample Size and Power Calculation for Immuno-Oncology Clinical Trials
Binbing Yu, MedImmune, Inc.; Dongyue FU, MedImmune, Inc.; Hefei (Harry) Yang, MedImmune, Inc.
4:20 PM
|
A Glimpse into Industry Experience with RWE to Transform Pharmaceutical Research and Development
James Harnett
4:25 PM
|
Inference and Optimal Design for Longitudinal Cluster-Randomized Clinical Trials Given a Small Number of Clusters with Application to a Serious Mental Illness Intervention Study
CHAE RYON KANG, University of Pittsburgh; DI ZHANG, University of Pittsburgh
4:50 PM
|
Design and Analysis of Cancer Immunotherapy Trials with Potential Violation of Proportional Hazards Assumption
Xiaofei Wang, Duke University School of Medicine; Guangyu Yang , University of Michigan
5:05 PM
|
A Hybrid Approach for Prediction of Event Times in Double-Blind Clinical Trials
Ming Zhu, Sanofi Pasteur; Yunnan Xu, Virginia Tech; Zheng Su, Deerfield Institute
5:05 PM
|
MCP-Mod Based Quantitative Techniques for Decision Making Process in Phase II Dose-Finding Clinical Trials
Na Cai, Astellas; Annie Wang, Astellas Pharma; Michael Smith, Astellas
5:20 PM
|
Novel Approach in Analyzing Difference in Binomial Proportions in Stratified Clinical Trials
Anindita Banerjee, Pfizer; Vivek Pradhan, Pfizer
5:35 PM
|
|
Monday, 07/30/2018
|
Randomization Tests in Randomized Clinical Trials: Beyond Population
Yanying Wang, George Mason University; Diane Uschner, RWTH Aachen University; William Fisher Rosenberger, George Mason University
|
Machine-Learning Approach to Defining Covariates to Increase Study Power in ALS Clinical Trials and Other Multifactorial Heterogeneous Disease Areas
Danielle Beaulieu, Origent Data Sciences; Albert Taylor, Origent Data Sciences; Samad Jahandideh, Origent Data Sciences; David Ennist, Origent Data Sciences; Andrew Conklin, Origent Data Sciences; Mike Keymer, Origent Data Sciences
|
Composite Endpoints for Alzheimer's Disease Clinical Trials
Steve Edland, University of California, San Diego
|
Open Data Sharing and Its Statistical Limitations
Pooja Iyer, RTI International; Barbara Do, RTI International
|
Symptom Trials Vs Morbidity/Mortality Trials: Are Different Estimands Required?
Steven Snapinn, Amgen, Inc.
8:35 AM
|
Formulation of Data Monitoring Committee Recommendations for Adaptive Design Clinical Trials
Navneet Hakhu, Axio Research
8:50 AM
|
Improving the Design of Pragmatic Clinical Trials Using Data Collected from Electronic Medical Records
Susan Shortreed, Kaiser Permanente Washington Health Research Institute; Carlyn M Rutter, RAND Corporation; Andrea J. Cook, Kaiser Permanente Washington Health Research Institute; Greg Simon, Kaiser Permenete Washington Health Research Insitute
9:15 AM
|
Open Data Sharing and Its Statistical Limitations
Pooja Iyer, RTI International; Barbara Do, RTI International
9:35 AM
|
Sample Size Considerations for Comparing Dynamic Treatment Regimens in a Sequential Multiple-Assignment Randomized Trial with a Continuous Longitudinal Outcome
Nicholas J Seewald, University of Michigan; Kelley M Kidwell, University of Michigan; James R McKay, University of Pennsylvania; Inbal Nahum-Shani, University of Michigan; Daniel Almirall, University of Michigan
9:35 AM
|
Data Enriched Generalized Linear Methods
Sayan Dasgupta, Fred Hutchinson Cancer Research Center; Cheng Zheng, University of Wisconsin at Milwaukee ; Ying Qing Chen, Fred Hutchinson Cancer Research Center; Asad Haris, University of Washington
10:35 AM
|
Leveraging Omics Biomarker in Early Clinical Trials - Concept, Utility and Impact on Decision Making
Weidong Zhang, Pfizer Inc.
10:35 AM
|
Use of Piecewise Weighted Log-Rank Test for Trials with Delayed Treatment Effect
Boguang Zhen, FDA; Zhenzhen Xu , FDA; Bin Zhu, NIH/NCI; Yongsoek Park, Unversity of Pittsburgh
11:25 AM
|
An Application of 2-In-1 Adaptive Phase 2/3 Design for Expedited Oncology Drug Development
Xinqun (Maggie) Chen, Merck & Co., Inc.; Linda Sun, Merck & Co., Inc.; Cong Chen, Merck & Co.
2:05 PM
|
A Location-Adjusted Approach to the Covariate-Adjusted Response-Adaptive Allocation Design in Multi-Center Trials
Brian S Di Pace, Virginia Commonwealth University; Roy T Sabo, Virginia Commonwealth University; David C. Wheeler, Virginia Commonwealth University
2:10 PM
|
Critical Steps for Composite Endpoint Analysis
Jerry J. Li, Merck & Co., Inc.
2:20 PM
|
Phase I Designs That Allow for Uncertainty in the Attribution of Adverse Events
Alexia Iasonos, Memorial Sloan Kettering Cancer Center; John O'Quigley, Universit'e Pierre et Marie Curie,
2:35 PM
|
A Strategy for the Design and Analysis of Bridging Studies
Eric Holmgren, Beigene
2:50 PM
|
A Parametric Multiple Comparison Procedure for Clinical Trials with Planned Evaluation of Treatment Effect in Pre-Defined Subgroups and Interim Analyzes
Liang Fang, MyoKardia; Ron Yu, Gilead Sciences, Inc.; Zhishen Ye, Gilead Sciences; Neby Bekele, Gilead Sciences; Ming Lin, Gilead Sciences
3:05 PM
|
Bayesian Isotonic Optimal Dose Design for Phase I/II Clinical Trials with Ordered Groups
Xiaoqiang Xue
3:05 PM
|
Statistical Approaches for Assessing the Utility of Urinary Glycosaminoglycans as a Surrogate Endpoint in Clinical Trials
Di Xiao, The Food and Drug Adminstration; Yeh-Fong Chen, US FDA; Min Min, U.S. Food and Drug Administration, CDER/OTS/OB
3:05 PM
|
Evaluation of Regional Efficacy Equivalence in Developing Biosimilars
Ryuji Uozumi, Kyoto University Graduate School of Medicine; Shinjo Yada, A2 Healthcare Corporation
3:20 PM
|
|
Tuesday, 07/31/2018
|
Assessing Reproducibility When Making Mid-Course Changes in Clinical Trials Based on External Data
Yingqi Shi, Johnson & Johnson-Janssen R&D; Grace Gao, Janssen R&D; Keith Karcher, Janssen R&D
|
Sample Size and Assurance Probability Calculation in Multi-Regional Clinical Trials
Zuoshun Zhang, Celgene Corporation
|
Transforming Data: a Case Study Using C-Peptide Data from Type 1 Diabetes Clinical Trials
Lia Weiner, Rho; Lynette Keyes-Elstein, Rho; Karen Boyle, Rho
|
Patient- and Site-Level Factors Associated with Abstinence Outcome in a Multisite Clinical Trial of a Technology-Delivered Psychosocial Intervention for Substance Use Disorders
Martina Pavlicova, Columbia University; Leila M. Vaezazizi, New York State Psychiatric Institue; Aimee N. C. Campbell, New York State Psychiatric Institute; Mei-Chen Hu, Columbia University; Edward V. Nunes, New York State Psychiatric Institute
|
Applications of Neural Net Models to Identify Placebo Responders in Clinical Trials
Mikhail Dmitrienko, Blue Valley North High School
|
Methods for Combining Controlled and Uncontrolled Clinical Trials
Shuyan Sabrina Wan, Merck Research Lab; Yuan Feng, North Carolina State University; Hong Liu, Merck; Kenneth Koury, Pfizer
|
Endpoint and Time-To-Event Analyzes in Interim Clinical Trial Reports
Scott Diegel, University of Wisconsin-Madison; Ryan Zea, University of Wisconsin-Madison; Melissa Schultz, University of Wisconsin-Madison
|
An Evaluation of Statistical Methods with Missing Data in Small Clinical Trials
Takayuki Abe, Yokohama City University, School of Data Science; Kazuhito Shiosakai, Daiichi Sankyo Co., Ltd.; Manabu Iwasaki, Yokohama City University, School of Data Science
|
Non-Inferiority Margins in Superiority/Non-Inferiority Seamless Clinical Trials
Ellen Gurary, Boston University; Joe Massaro, Boston University
|
Adaptively Incorporating Supplemental Information in Clinical Trials in the Presence of Population Heterogeneity
Joseph Koopmeiners, Division of Biostatistics, University of Minnesota; Ales Kotalik, University of Minnesota; David Michael Vock, University of Minnesota
|
The Importance of Protocol Objectives to the Statistical Analysis
Richard McNally, Covance-Chiltern
|
Using Tradition to Guide Non-Traditional Decisions in Phase 1 Clinical Trials
Paul Frankel, City of Hope
|
Phase I Designs That Allow for Uncertainty in the Attribution of Adverse Events
Alexia Iasonos, Memorial Sloan Kettering Cancer Center; John O'Quigley, Universit'e Pierre et Marie Curie,
|
Discovering Biomarkers Jointly Modeled with Multiple Efficacy Variables in Early Phase Clinical Trials
Danni Yu, Eli Lilly and Company
|
Performance Comparison of Post-Hoc Subgroup Search Algorithms for Clinical Trials
Victor Talisa, University of Pittsburgh; (Joyce) Chung-Chou H. Chang, University of Pittsburgh
|
A Location-Adjusted Approach to the Covariate-Adjusted Response-Adaptive Allocation Design in Multi-Center Trials
Brian S Di Pace, Virginia Commonwealth University; Roy T Sabo, Virginia Commonwealth University; David C. Wheeler, Virginia Commonwealth University
|
Multiple Testing Procedure Consideration in Clinical Trials
Rachael Wen, Sanofi
|
Bridging Information Between Dose-Response Curves Across Populations in Early Phase Clinical Trials
Moreno Ursino, Inserm DR PA 6
|
Real-Time Study Milestone Projection in Clinical Trials with Time-To-Event Endpoints
Yanping Liu, Merck & Co.; Gang Jia, Merck & Co.
|
Design Considerations When Comparing Control, Treatment, and Treatment Plus in Randomized Trials
Abigail Shoben, Ohio State University
|
Statistical Approaches for Assessing the Utility of Urinary Glycosaminoglycans as a Surrogate Endpoint in Clinical Trials
Di Xiao, The Food and Drug Adminstration; Yeh-Fong Chen, US FDA; Min Min, U.S. Food and Drug Administration, CDER/OTS/OB
|
Social Media and Clinical Research
Darcy Hille, Merck & Company Inc; T. Ceesay, Merck
8:35 AM
|
Bridging Information Between Dose-Response Curves Across Populations in Early Phase Clinical Trials
Moreno Ursino, Inserm DR PA 6
8:45 AM
|
Incorporating Historical Information into the Analysis of Clinical Trials- a Case Study
Guochen Song, Biogen; Yiqing Tian, Q2 Sulotions; John Zhong, Biogen; Stacy Lindborg, Biogen Idec
8:50 AM
|
The Myth of Making Inference for Overall Treatment Efficacy with Data from Multiple Studies via Meta-Analysis
Brian Claggett, Harvard Medical School
8:55 AM
|
Discovering Biomarkers Jointly Modeled with Multiple Efficacy Variables in Early Phase Clinical Trials
Danni Yu, Eli Lilly and Company
9:10 AM
|
Design Considerations in Clinical Trials with Cure Rate Survival Data: a Case Study in Oncology
Grace Liu, Johnson & Johnson; Steven Sun, J&J; Tzu-min Yhe, janssen pharmaceuticals; Tianmeng Lyu, University of Minnesota; Rao Sudhakar, janssen pharmaceuticals; Bruce Xue, Johnson & Johnson China
9:20 AM
|
Multiplicity Adjustment for Multiple Endpoints Testing in Overall and Subgroup Populations
Libo Sun, Janssen Pharmaceutical R&D; Grace Liu, Johnson & Johnson; Rui Qin, Janssen Pharmaceutical R&D
9:35 AM
|
Performance Comparison of Post-Hoc Subgroup Search Algorithms for Clinical Trials
Victor Talisa, University of Pittsburgh; (Joyce) Chung-Chou H. Chang, University of Pittsburgh
9:40 AM
|
Statistical Leadership in Clinical Trials: Opportunities from the Draft Estimand Guidance
Jonathan Siegel, Bayer HealthCare Pharmaceuticals Inc.
9:50 AM
|
Real-Time Study Milestone Projection in Clinical Trials with Time-To-Event Endpoints
Yanping Liu, Merck & Co.; Gang Jia, Merck & Co.
9:50 AM
|
Safety Analysis of Clinical Trials in NDA Submissions
Linyun Zhou, Takeda Global Research & Development
10:05 AM
|
On the Relationship Between the Causal-Inference and Meta-Analytic Paradigms for the Evaluation of Surrogate Endpoints
Geert Molenberghs, Universiteit Hasselt & Katholieke Universiteit Leuven
10:35 AM
|
Reversals in Early Phase Dose Finding Trials
Bethany Horton, University of Virginia; John O'Quigley, Universit'e Pierre et Marie Curie, ; Mark Conaway, University of Virginia
10:35 AM
|
The Impact of Misspecification of Linear Modeling on the Prediction in SMART PK/PD Clinical Trials
Tian Zhao, Merck; Li Fan, Merck
11:20 AM
|
Multiple Testing Procedure Consideration in Clinical Trials
Rachael Wen, Sanofi
11:30 AM
|
Estimation of Treatment Effect in Enriched Clinical Trials: Application to Multiple Sclerosis
Rachel MacKay Altman, Simon Fraser University
11:35 AM
|
Identifying and Validating Surrogate Endpoints for Overall Survial (OS) in Metastatic Castration-Resistant Prostate Cancer
Xiaowei Guan, Pfizer, Inc.; Michelle Casey, Pfizer, Inc.; De Phung, Astellas Pharma, Inc. ; Suha Sari, Pfizer, Inc.; Eren Demirhan, Pfizer, Inc.
11:35 AM
|
Biomarker-Defined Subgroup Selection Adaptive Design for Phase III Confirmatory Trial
Rui Tang, Shire; Xiaoye Ma, University of Minnesota; Hui Yang, Amgen Inc.
11:50 AM
|
Estimating Directed Acyclic Graphs from High-Dimensional Data and Its Application in Biomarker Discoveries in Early Clinical Trials
Hua Zhong, New York University; Jaehong Yu, NYU School of Medicine
11:55 AM
|
Integrating Data from Clinical Trials for More Powerful Mediation and Interaction Analyzes
Linda Valeri, McLean Hospital, Harvard Medical School; Yiwen Zhu, Massachussetts General Hospital; Franca Centorrino, McLean Hospital; Garrett Fitzmaurice, McLean Hospital
11:55 AM
|
Design Considerations When Comparing Control, Treatment, and Treatment Plus in Randomized Trials
Abigail Shoben, Ohio State University
12:05 PM
|
Analysis of Stratified Clinical Trials with Time-To-Event Endpoints
Devan V Mehrotra, Merck & Co., Inc.; Shanjun Helian, Merck & Co., Inc.; Shu-Chih Su, Merck Research Labs
3:05 PM
|
Reproducibility of FDG-PET Standardized Uptake Value (SUV) for Use as an Integral Biomarker in Clinical Trials
Brenda Kurland, University of Pittsburgh
3:05 PM
|
A Bayesian Hierarchical Model Estimating CACE in Meta-Analysis of Randomized Clinical Trials with Noncompliance
Jincheng Zhou, University of Minnesota; Haitao Chu, University of Minnesota Twin Cities; James S. Hodges, University of Minnesota; M. Fareed Khan Suri, University of Minnesota
3:25 PM
|
|
Wednesday, 08/01/2018
|
When Do We Really Need Randomized Clinical Trials?
Christopher Hane, OptumLabs; William Crown, OptumLabs
|
MMRM Estimates Consideration for Longitudinal Data in Clinical Trials
Yaohua Zhang, Vertex Pharmaceuticals; Zheng (Jason) Yuan, Vertex Pharmaceuticals; Chenkun Wang, Vertex Pharmaceuticals; Bingming Yi, Vertex Pharmaceuticals
|
Statistical Considerations of Single Pivotal Vs Two Replicated Confirmatory Studies
Zijiang Yang, Janssen R&D
|
Subgroup Selection in Adaptive Signature Designs of Confirmatory Clinical Trials
Zhiwei Zhang, University of California at Riverside
8:35 AM
|
Moving Beyond Longrank/Hazard Ratio Test/Estimation Approach in Cancer Clinical Trials
Hajime Uno, Dana Farber Cancer Institute; Miki Horiguchi, Kitasato University
8:35 AM
|
Incorporating Intermediary Information in Cox Models of Randomized Clinical Trials: The Information Balanced Intermediary Cox Model
James Troendle, National Institutes of Health; Eric Leifer, National Heart, Lung, and Blood Institute; Lauren Kunz, National Heart, Lung, and Blood Institute; Song Yang, NHLBI/NIH
8:50 AM
|
MMRM Estimates Consideration for Longitudinal Data in Clinical Trials
Yaohua Zhang, Vertex Pharmaceuticals; Zheng (Jason) Yuan, Vertex Pharmaceuticals; Chenkun Wang, Vertex Pharmaceuticals; Bingming Yi, Vertex Pharmaceuticals
9:15 AM
|
A Curtailed Two-Stage Selection and Testing Procedure for Comparative Clinical Trials
Mingyue Wang, Syracuse University; Pinyuen Chen, Syracuse University
9:35 AM
|
Tools and Techniques for Blinded Data Reviews in Ongoing Clinical Trials
Suresh Ankolekar, Cytel Inc.; Hrishikesh Kulkarni, Cytel Inc.
9:55 AM
|
Composite Endpoints in Clinical Trials with Multiple Correlated Dichotomous Outcomes
Boris Zaslavsky, FDA/CBER
10:05 AM
|
Statistical Considerations of Single Pivotal Vs Two Replicated Confirmatory Studies
Zijiang Yang, Janssen R&D
10:05 AM
|
Novel Model-Assisted Designs for Phase I Drug Combination Trials
Ruitao Lin, MD Anderson Cancer Center
10:35 AM
|
Asymptotic MinP Method for Responder Analysis
Ming Zhou, Bristol-Myers Squibb Company; Mark Donovan, Bristol-Myers Squibb
10:35 AM
|
A Simulation Study of Consistency Evaluation Between Local and Global Results in Multi-Regional Clinical Trials
Chunsheng He, Bristol-Myers Squibb; Jingyi Lin, Duke University; Stephane Munier, Bristol-Myers Squibb; Shein-Chung Chow, Duke University; Lisa Ying
10:50 AM
|
A Statistical Framework on Clinical Trials for Information Integration Across Data Sources with Applications to Rare Disease Clinical Development
Yang Song, Vertex Pharmaceuticals Inc.; Xihao Li, Harvard T.H. Chan School of Public Health
10:55 AM
|
Bayesian Uncertainty Directed Trial Designs
Lorenzo Trippa, Harvard
11:05 AM
|
Bayes in Drug Development for Rare Diseases
John Scott, FDA
11:35 AM
|
Improving Testing and Description of Treatment Effect in Clinical Trials with Time-To-Event Outcomes
Song Yang, NHLBI/NIH
11:50 AM
|
Degrees of Freedom Adjustment in Mixed Model Repeated Measures Analyzes with Missing Data
Michael McDermott, University of Rochester Medical Center; Madhurima Majumder, Bayer Pharmaceuticals
2:05 PM
|
Approaches to Tipping Point Analyzes for a Binary Endpoint in Longitudinal Clinical Trials
Joseph Wu, Pfizer; Huaming Tan, Pfizer, Inc.; Neal Thomas, Pfizer; Cunshan Wang, Pfizer, Inc.
2:50 PM
|
The Application of Tipping Point Analysis in Clinical Trials
HONG DING
3:35 PM
|
|
Thursday, 08/02/2018
|
Dynamic Treatment Regimens for Superbug Infections
Dean Follmann, NIAID
8:35 AM
|
Inference for Clinical Trials That Rely on Historical Data: a Review of Statistical Approaches for Reducing Risk of Bias
Lei Nie, Division of Biometrics V, office of Biostatistics, CDER/FDA; James Signorovitch, Analysis Group; Rajeev Ayyagari, Analysis Group
8:55 AM
|
Does it Pay to Repeat the Baseline?
Shiyang Ma, University of Rochester; David Oakes , University of Rochester
9:05 AM
|
An Overview of Matching Adjusted Indirect Comparisons in Single Arm Clinical Trials with Practical Recommendations and Potential Challenges
Dawn Odom, RTI Health Solutions; Molly Purser, RTI Health Solutions; Lawrence Rasouliyan, RTI Health Solutions
9:15 AM
|
Pragmatic Benefit:Risk Evaluation: Healthy Disruption for Clinical Trials
Scott Evans, Harvard University; Ying Liu, Harvard University; Dean Follmann, NIAID
9:35 AM
|
Bayesian Extrapolation in Pediatric Clinical Trials
Mehreteab F Aregay, Novartis; David Ohlssen, Novartis; Heinz Schmidli, Novartis Pharamceutical Corporation
10:05 AM
|
Evaluating Biomarkers for Prognostic Enrichment of Clinical Trials
Kathleen F. Kerr, University of Washington; Jeremy Roth, University of Washington; Kehao Zhu, Axio Research; Heather Thiessen-Philbrook, Yale University; Allison Meisner, Johns Hopkins University; Francis Perry Wilson, Yale University; Steven Coca, Icahn School of Medicine at Mount Sinai; Chirag Parikh, Yale University
10:35 AM
|
A Simulation Study Comparing MCP-Mod and a Model-Based Approach in Phase 2a Clinical Trials
Hongtao Zhang; Alan Hartford, AbbVie Inc
10:35 AM
|
Quantitative Assessment of Risk with Subgroup Pursuit in Clinical Trials
Xinzhou Guo, University of Michigan; Xuming He, University of Michigan
10:35 AM
|
Adaptive Bayesian Interval-Based Oncology Dose Finding Design with Quasi-Continuous Toxicity Model
Dan Zhao, University of Illinois at Chicago; Jian Zhu, Takeda; Eric Westin, ImmunoGen; Ling Wang, Takeda
10:50 AM
|
Bias-Corrected Estimation of Treatment Effects in Biomarker-Based Adaptive Subgroup Analysis: New Approach Based on Randomized Tests with Smooth Rejection Function
Kiichiro Toyoizumi, Shionogi Inc.; Shigeyuki Matsui, Nagoya University
11:05 AM
|
Deriving and Analyzing Endpoints from Electronic Health Record Data: a Case Study from Clinical Oncology
Sandra Griffith, Flatiron Health; Ariel Bourla, Flatiron Health; Bryan Bowser, Flatiron Health ; Geoff Calkins, Flatiron Health; Joe Chang, Flatiron Health; Rebecca Miksad , Flatiron Health ; Brian Segal, Flatiron Health; Elizabeth Sweeney, Flatiron Health ; Erin Williams, Flatiron Health ; Paul You , Flatiron Health ; Amy Abernethy, Flatiron Health
11:15 AM
|
On Evaluation of Consistency in Multi-Regional Clinical Trials
Lisa Ying; Fuyu Song, Center for Food and Drug Inspection, cFDA; Shein-Chung Chow, Food and Drug Administration; Na Zeng, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital; Jiayin Zheng, Fred Hutchinson Cancer Research Center; Xiaodong Li, Bristol-Myers Squibb Company; David Henry, Bristol-Myers Squibb Company; Venkat Sethuraman, ZS Associates
11:35 AM
|
An Adaptive Dose Selection Case Study: Statistical Methods and Operational Considerations
Adam Hamm, Cytel, Inc.
11:35 AM
|
Marginal Meta-Analysis for Combining Multiple Randomized Clinical Trials with Rare Events
Yi Huang, University of Maryland, Baltimore County; Elande Baro, US FDA; Yun-Ju Cheng, University of Maryland, Baltimore County; Guoxing Song, US FDA
11:35 AM
|
Statistical Arguments for Regulatory Negotiation on Promising Subgroup Results
Ming-Xiu Hu, Nektar Therapeutics
11:35 AM
|
Statistical Monitoring of Semi-Competing Risk Outcomes in Clinical Trials
Toshi Hamasaki; Scott Evans, Harvard University; Tomoyuki Sugimoto, Kagoshima University; Koko Asakura, National Cerebral and Cardiovascular Center; Susan Halabi, Duke University
11:50 AM
|
|
|
